Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triptorelin 3-month formulation in Chinese children with central precocious puberty
2022-002963-31Phase 3
- Sponsor
- Ipsen
- Start
- Jan 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of triptorelin pamoate in central precocious puberty (CPP), sponsored by Ipsen. Primary endpoint: Proportion of children with luteinizing hormone suppression.
02
Drugs
triptorelin pamoate
03
Conditions
central precocious puberty (CPP)
Beyond the preview
Go deeper on 2022-002963-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002963-31.